This is a medicine to prevent heart attacks and strokes in patients who suffer acutecoronarysyndrome, the condition that occurs after a heart attack or serious heart-related chest pain.
Gail Cawkwell , a medical director at Pfizer, said that the drug giant would not be conducting a trial in patients with acutecoronarysyndrome, but instead in patients at high risk for heart attacks.